Ammerschwihr, France

Jean-Christophe Peter


Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2011-2015

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Jean-Christophe Peter

Introduction

Jean-Christophe Peter is a notable inventor based in Ammerschwihr, France. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of three patents to his name, his work focuses on innovative treatments for various medical conditions.

Latest Patents

One of his latest patents involves antibodies against tropomyosin-related kinase B receptors. This invention relates to monoclonal antibodies directed to a specific part of the tropomyosin-related kinase B receptor (TrkB) and hybridoma cell lines that produce these antibodies. The fragments of these antibodies, especially those representing complementarity determining regions (CDRs), are useful in treating cancer, pain, anorexia, anorexia nervosa, and cachexia. Another significant patent pertains to monoclonal antibodies and binding fragments directed to the human melanocortin-4 receptor. This patent includes pharmaceutical compositions and therapeutic uses for treating cachexia and related conditions.

Career Highlights

Jean-Christophe Peter has worked with prestigious institutions, including the University of Basel and Universitaet Basel. His research and innovations have contributed to advancements in medical treatments, showcasing his expertise in the field.

Collaborations

He has collaborated with Karl Hofbauer, further enhancing the impact of his research and inventions.

Conclusion

Jean-Christophe Peter's work in developing monoclonal antibodies represents a significant advancement in biotechnology. His innovative patents have the potential to improve treatment options for various medical conditions, highlighting his role as a key inventor in this field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…